Navigation Links
Sagent Pharmaceuticals Announces Extension of Series A Financing
Date:5/20/2009

SCHAUMBURG, Ill., May 20 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has raised $30 million in a second Series A financing extension with pre-existing and new strategic investors. The round was again led by Vivo Ventures. This capital will be used to support upcoming product launches, development activities and strategic business objectives.

"Sagent's business model unites extensive pharmaceutical development, regulatory and manufacturing capabilities with the unique strength of our U.S. focused sales and marketing team to provide our hospital and clinical customers with a broad range of the highest quality injectable products," said Jeffrey M. Yordon, chief executive officer, founder and chairman of the board of Sagent Pharmaceuticals. "Since our inception in 2006, Sagent has successfully executed its strategy by filing more than 70 aNDAs to date, with more than 20 products expected in the market by year end. We appreciate our investors' continued confidence and commitment to Sagent."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
3. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
4. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
5. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... EpiGentek , a Farmingdale, NY-based ... RNA methylation “gold rush” with their established portfolio of optimized assay kits that ... or m6A , RNA methylation has received a new burst in interest ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association ... chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. ... “Increasingly, supply chain and value analysis professionals have a ‘seat at the table’ ...
(Date:3/27/2017)... Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... men with prostate cancer, including all stages, is more than 95%. Once the cancer ... drastically to less than 30%. To find out how to avoid this latter group, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... sodium testing methods are complicated and require expert user knowledge. In a live ... method dedicated to the simplified, yet highly accurate, determination of sodium. , It ...
(Date:3/27/2017)... ... 2017 , ... ?Grow Healthy Vending LLC announced today that ... itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ United States ... that we have now reached a settlement agreement regarding the ongoing lawsuits between ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
(Date:3/27/2017)... Israel , March 27, 2017 ... oncology and immunology, announced today that AGI-134, an immunotherapy for ... acquisition of Agalimmune Ltd., will be featured at the upcoming ... in Washington, DC to be held ... ...
(Date:3/27/2017)... 27, 2017 The global ... 16.0 billion by 2025, according to a new study ... chronic diseases is anticipated to be responsible for the ... widens the scope for growth during the forecast period. ... which is highly susceptible to chronic diseases, is presumed ...
Breaking Medicine Technology: